1,1'-azobisformamide - July, p. 201
141W94 - Feb., p. 37; July, p. 202; Oct., p. 297, 298
1592U89 (use abacavir)
3TC (use lamivudine)
abacavir - Apr., p. 102; July, p. 199; Aug., p. 233; Oct., p. 297; Nov., p. 333
AccuSite Injectable Gel - Mar., p. 76; Aug., p. 236; Sep., p. 259
acyclovir - May, p. 135; June, p. 166; Aug., p. 225
acyclovir, controlled release - Feb., p. 35; Nov., p. 333
acyclovir, generic - Apr., p. 105; July, p. 202
adefovir dipivoxil - Feb., p. 40; May, p. 138; Dec., p. 366
Adjumer vaccines/adjuvants - Mar., p. 78; Apr., p. 10; Nov., p. 329
AG1343 (use nelfinavir)
Aldara - Mar., p. 66
Alferon N Injection - June, p. 170
AlphaLeukoferon - Nov., p. 328
Alphanate Antihemophilic Factor (Human) - Mar., p. 76
aluminum adjuvants - Nov., p. 329
ALX40-4C - Feb., p. 38
AM94 - Aug., p. 236
aminooxypentane-RANTES - Aug., p. 231
Amplicor HIV-1 Monitor Test - Aug., p. 230
Ampligen - Feb., p. 39; Mar., p. 74; May, p. 141; Aug., p. 232; Sep., p. 269
AndroVir - Mar., p. 72; June, p. 172
Anticort - Feb., p. 42
antisense oligonucleotides - Feb., p. 41; Mar., p. 69; May, p. 130, 134, 135; July, p. 200; Aug., p. 226; Sep., p. 264, 265
Arilvax - Oct., p. 301
AZT - Feb., p. 44; May, p. 135, 141; June, p. 161, 167 , 170; Aug., p. 233; Oct., p. 297, 300; Dec., p. 357
AZT/lamivudine combination tablet (use Combivir)
BCX-34 - May, p. 136
beta-L-Fd4C - Sep., p. 271
BIRR 4 - Dec., p. 362
bis(POM)PMEA (use adefovir)
BMS-200475 - Nov., p. 328
BMS-232623 - June, p. 174
BMS-234475 - June, p. 174
BOB - Aug., p. 231
Bonzo - Aug., p. 231
calanolides - May, p. 133; June, p. 169; Nov., p. 334
camptothecins - Aug., p. 238
carbovir (use abacavir)
CCR2 - Aug., p. 231
CCR5 - Aug., p. 231; Sep., p. 265
CD26 immune modulators - Dec., p. 365
CD4 - Sep., p. 261
CGP-61755 - June, p. 174
CGP-73547 - June, p. 174
CGP-64222 - Aug., p. 229
chemokines - May, p. 134; June, p. 169; Aug., p. 231; Sep., p. 266; Nov., p. 325; Dec., p. 360
chickenpox vaccines - May, p. 142; Dec., p. 360
ChimeriVax vaccines - Oct., p. 301
Chinese herbs - Nov., p. 333
CI-1012 - Apr., p. 102
cidofovir - Feb., p. 43; May, p. 136; Nov., p. 325; Dec., p. 365
cidofovir gel - Mar., p. 73; May, p. 140
CMV antibodies, humanized - June, p. 164; July, p. 198
CMV antibodies, polyclonal - Aug., p. 236
cochleate vaccines - Apr., p. 104
Combivir - July, p. 204; Oct., p. 292
Condylox Gel - Apr., p. 106
CoolPure - Nov., p. 334
Crixivan (use indinavir sulfate)
CXCR4 - Sep., p. 261
CY2301 - Feb., p. 40
CytoGam - Aug., p. 236
Cytovene (use ganciclovir)
D4T - Feb., p. 41, 44; Apr., p. 101; Aug., p. 234; Oct., p. 295, 298, 300
DDC - June, p. 161
DDI - Apr., p. 101; July, p. 203; Sep., p. 260; Oct., p. 295
delavirdine - Apr., p. 97
Denavir (use penciclovir cream)
Dengue vaccines - Feb., p. 46; Oct., p. 301
diabetes mellitus, insulin dependent - Nov., p. 331
Disabled Infectious Single Cycle (DISC) vaccines - Apr., p. 107
DMP 266 - Feb., p. 38; June, p. 165; Sep., p. 258
DMP 450 - July, p. 198
DNA plasmid vaccines - Nov., p. 330, 335
Epivir (use lamivudine)
Epstein-Barr virus vaccines - Dec., p. 361
Expaxal Berna - Sep., p. 264
famciclovir - May, p. 129, 137; June, p. 166; Aug., p. 229; Sep., p. 257; Oct., p. 295
Famvir (use famciclovir)
fluorouracil (use AccuSite Injectable Gel)
Flustat - Sep., p. 267
Fluviral S/F - May, p. 132
fomivirsen sodium (use ISIS 2922)
Fortovase - Feb., p. 41; May, p. 141; Sep., p. 260; Oct., p. 296; Nov., p. 324
Forvade (use cidofovir gel)
foscarnet - Mar., p. 67; Nov., p. 325
foscarnet, lipid conjugate - June, p. 164
foscarnet, topical - Oct., p. 298
Foscavir (use foscarnet)
ganciclovir - Mar., p. 67; Nov., p. 325
ganciclovir, implant - June, p. 168; Oct., p. 294; Nov., p. 329
ganciclovir, oral - May, p. 132; Oct., p. 294
ganciclovir valinate HCl (use valganciclovir)
GEM 91 - Mar., p. 69; May, p. 130; Aug., p. 226
GEM 92 - Sep., p. 264
GEM 132 - Feb., p. 41
gene therapy, HIV - Mar., p. 75; Dec., p. 365
gene therapy, interferon-beta - Dec., p. 364
gene therapy, ribozymes - Feb., p. 38
GPI-2A - June, p. 165
granulocyte macrophage-colony stimulating factor (GM-CSF) - May, p. 136; Sep., p. 263
GS 3857 - Feb., p. 42
GS 4104 - Feb., p. 42; July, p. 203; Oct., p. 294
GS 840 (use adefovir)
H-BIG 5% I.V. - Aug., p. 228; Nov., p. 331
Havrix - July, p. 205
HCV C9 strain - Feb., p. 46
Hepagene - Dec., p. 355
hepatitis A virus (HAV) vaccines - July, p. 205; Sep., p. 264
hepatitis B antibodies, humanized - June, p. 164
hepatitis B immune globulin - Aug., p. 228; Nov., p. 331
hepatitis B virus vaccines - Feb., p. 43; Aug., p. 235; Nov., p. 330, 335; Dec., p. 355
hepatitis C virus helicase - June, p. 165
hepatitis C virus nonstructural 5A (NS5A) protein - June, p. 169
hepatitis C virus protease inhibitors - June, p. 164; Sep., p. 271; Dec., p. 367
hepatitis C virus vaccines - Oct., p. 301
hepatitis E virus vaccines - Sep., p. 264
herpes simplex virus heteroconjugate vaccines - Oct., p. 298
herpes simplex virus vaccines - Oct., p. 301
herpes simplex virus type 2 vaccines - Apr., p. 107
HGP-30 - Feb., p. 43; May, p. 136; Sep., p. 263
HGP-30W - July, p. 204
HIV & Herpes Peptide - Mar., p. 75
HIV activated lymphocytes - June, p. 167; Dec., p. 363
HIV antibodies, monoclonal - Mar., p. 75 Sep., p. 266
HIV antibodies, recombinant - Mar., p. 70
HIV antisense oligonucleotides - June, p. 165
HIV DNA plasmid vaccines - May, p. 139; Aug., p. 228
HIV gp120 vaccines - July, p. 201
HIV immune globulin (HIV-IG) - Mar., p. 75; Apr., p. 102; Dec., p. 362
HIV integrase inhibitors - Oct., p. 299
HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs) - Feb., p. 38, 42, 43; Apr., p. 107, 97; May, p. 133, 138; June, p. 165, 169; Aug., p. 234; Oct., p. 296, 299; Nov., p. 334
HIV p7 antigen - Feb., p. 46
HIV passive hyperimmune therapy (PHT) - Feb., p. 45
HIV protease inhibitors - Feb., p. 33, 35, 36, 37, 41; Mar., p. 65, 75; Apr., p. 103; May, p. 139, 141; June, p. 168, 172, 174; July, p. 198, 202; Oct., p. 292, 297, 298, 300; Nov., p. 332
HIV protein-tyrosine kinase inhibitors - Mar., p. 72; June, p. 172
HIV Rev M10 gene therapy - Dec., p. 365
HIV Tat inhibitors - Feb., p. 38; Aug., p. 229
HIV topoisomerase I inhibitors - Aug., p. 238
HIV TruGene genotyping kits - Oct., p. 299
HIV vaccines - Feb., p. 40, 43; Mar., p. 72, 76; May, p. 134, 136, 138; June, p. 163, 169; July, p. 201, 204; Sep., p. 263, 267, 268; Nov., p. 335
HIV vaccines, cloned HIV - Dec., p. 353
HIV vaccines, live - Aug., p. 227; Dec., p. 353
HIV vaccines, prime-plus-boost - May, p. 138; July, p. 201
HIV zinc finger inhibitors - Apr., p. 102
HIV-IT (V) vaccine - Mar., p. 73
Hivid (use DDC)
HNK20 - Apr., p. 100; Nov., p. 329
HRG214 - Mar., p. 70
human chorionic gonadotropin (hCG) - Apr., p. 103
human papillomavirus vaccines - Feb., p. 37; Apr., p. 108; Dec., p. 364
HYB 101400 - May, p. 135
hydroxyurea - Sep., p. 260
ICAM-1 rhinovirus receptor - Dec., p. 362
imiquimod - Mar., p. 66
inactivation, hydroxymethylglycinate - Sep., p. 266
inactivation, photo- - Nov., p. 334
inactivation, pulsed electrical fields - Nov., p. 334
inactivation, solvent detergent - Mar., p. 76
indinavir - Feb., p. 35; Apr., p. 104; June, p. 167; July, p. 199, 203; Oct., p. 292, 296, 298
indinavir, NanoCrystal suspension - Feb., p. 39
Infanrix Hep B - Aug., p. 235
Infergen (use interferon alfacon-1)
influenza neuraminidase inhibitors - July, p. 203
influenza vaccines - Mar., p. 74; Apr., p. 104; May, p. 132, 137; July, p. 193; Sep., p. 267; Nov., p. 329, 334
interferon alfa-n3 - June, p. 170
interferon alfacon-1 - Aug., p. 239; Oct., p. 289
interferon alpha - June, p. 168; July, p. 201; Nov., p. 328
interferon alpha-2b - Apr., p. 106; Sep., p. 263, 265; Oct., p. 298; Nov., p. 324; Dec., p. 365
interferon beta - Apr., p. 107; May, p. 142
interferon, low-dose oral - Aug., p. 236, 239; Sep., p. 265; Nov., p. 326
interleukin-2 (IL-2) - Mar., p. 71; Apr., p. 100
intracellular chemokines (intrakines) - Dec., p. 360
Intron A (use interferon alpha-2b)
Invirase - Feb., p. 41; June, p. 161; Dec., p. 363
ISIS 2922 - June, p. 163; July, p. 200
ISIS 5320 - Feb., p. 40
Japanese encephalitis vaccines - Feb., p. 46; Oct., p. 301
lamivudine - Apr., p. 99; May, p. 135; June, p. 162, 170; July, p. 203; Aug., p. 234; Oct., p. 297, 300; Nov., p. 332; Dec., p. 357
leishmanial eukaryotic initiation factor (LeIF) - Mar., p. 78
Lexirin - June, p. 165
Lidakol - Mar., p. 75; Apr., p. 105; Aug., p. 225
Ligand Epitope Antigen Presentation System - Oct., p. 298
LiPA HIV-1 Reverse Transcriptase test - June, p. 170
Liposome-CD4 - May, p. 134
lobucavir - Nov., p. 328
Maxamine H2 receptor agonist - July, p. 201
MEDI-493 - (use RSV monoclonal antibodies)
MEDI-501 - Feb., p. 37
MKC-442 - Feb., p. 43; Apr., p. 107; Oct., p. 299
monoclonal antibodies, transgenic mice - Feb., p. 46
monophosphoryl lipid adjuvants - Apr., p. 108
MP 266 - Aug., p. 234
N-acetylneuraminic acid, 4-gaunidino-2,4-dideoxy-2,3-dehydro- - Oct., p. 292
n-docosanol (use Lidakol)
naphthalene sulfonate polymer - May, p. 139; July, p. 203
nelfinavir - Feb., p. 33, 37, 39; Mar., p. 65, 75; Apr., p. 103; May, p. 140; July, p. 200; Aug., p. 234
nevirapine - Feb., p. 42; May, p. 138; Aug., p. 234; Oct., p. 296
nonoxynol-9 - Apr., p. 104
Norvir (use ritonavir)
nucleosides, anti-HIV - June, p. 171
nutraceuticals - Mar., p. 72; June, p. 172
Omniferon - Nov., p. 328
Optivax (vaccine delivery) - Feb., p. 39
Oxoferin - Sep., p. 261
paclitaxel - Sep., p. 269
PEG-interferon alfa-2b - Sep., p. 267
penciclovir cream - May, p. 131
penciclovir, i.v. - Aug., p. 229
pentafuside - July, p. 204
plant drugs - Mar., p. 76
pleconaril - May, p. 139; July, p. 201
PMPA - Feb., p. 42; May, p. 133
podophyllotoxin - Apr., p. 106
poliovirus vaccines - Apr., p. 106; Sep., p. 262
poly[di(carboxylatophenoxy)phosphazene] (PCPP) - Nov., p. 329
poly I:poly (C12U) [use Ampligen]
PowderJect gene delivery device - Nov., p. 330
PRO 2000 Gel - May, p. 139; July, p. 203
procaine HCl - Feb., p. 42
Protovir - June, p. 164; July, p. 198
PureBright - Nov., p. 334
QS-21 Stimulon adjuvant - May, p. 139
QuickVue Generation III HSV-2 assay - Oct., p. 300
(R)-9-(2-phosphonylmethoxypropyl)adenine (use PMPA)
RabAvert - Nov., p. 323
rabies vaccines - July, p. 206; Nov., p. 323
red blood cells-CD4 - July, p. 202
Remune - May, p. 134
Rescriptor (use delavirdine)
RespiGam (use RSV immune globulin)
reticulose - Mar., p. 73
Retrovir (use AZT)
rhinovirus 3C protease inhibitors - May, p. 140
ribavirin - Sep., p. 263; Nov., p. 324; Dec., p. 365
ribozymes - Feb., p. 39; June, p. 166
ritonavir - Mar., p. 67, 75; Dec., p. 363
rotavirus vaccines - Mar., p. 70; July, p. 201; Aug., p. 236
RSV immune globulin - Mar., p. 73; Aug., p. 236
RSV monoclonal antibodies - Mar., p. 68; Apr., p. 100, 103; June, p. 167; July, p. 195, 206; Nov., p. 329; Dec., p. 359
Rubella Vaccine Live - Sep., p. 268
saquinavir, hard gel (use Invirase)
saquinavir, soft gel (use Fortovase)
sevirumab (use Protovir)
SIV, live interferon-expressing - Sep., p. 268
Skinner Vaccine - Oct., p. 301
SP-303 - May, p. 135
SPV-30 - Mar., p. 76
SteriPath - Sep., p. 266
stromal cell-derived factor-1 intrakine - Dec., p. 360
supra molecular biovectors - May, p. 132
Sustiva (use DMP 266)
Synovir - Mar., p. 71
T-20 - July, p. 204
TA-GW - Dec., p. 364
Taxol - Sep., p. 269
TBC-3B - July, p. 201
tetrachlorodecaoxygen - Sep., p. 261
thalidomide - Mar., p. 71
thymidylate kinase - Aug., p. 233
thymosin alpha 1 - June, p. 172; Sep., p. 271; Nov., p. 333
topical anesthetics - Sep., p. 266
translation inhibitors - Oct., p. 298
trifluridine - May, p. 137
tumor necrosis factor monoclonal antibody - Mar., p. 71
vaccines - Feb., p. 45; Aug., p. 235
vaccines, edible plants - Feb., p. 43; Nov., p. 336
valacyclovir - Oct., p. 291; Nov., p. 325
valganciclovir - June, p. 168; Nov., p. 333
Valtrex (use valacyclovir)
Varicella Virus Vaccine Live - Dec., p. 360
varicella-zoster virus immune globulin - Nov., p. 332
vCP205 - May, p. 138
Videx (use DDI)
Viracept (use nelfinavir)
Viramune (use nevirapine)
Virazole (use ribavirin)
Virend - May, p. 135
Viroptic Ophthalmic Solution - May, p. 137
Viropump - Feb., p. 35
Vistide (use cidofovir)
Vitrasert Implant (use ganciclovir, implant)
vMIP-II - Nov., p. 325
warts surgery - Sep., p. 266
WF10 - Sep., p. 261
XQ-9302 - Nov., p. 333
yellow fever virus vaccines/vectors - Oct., p. 301
Zadaxin (use thymosin alpha 1)
zanamivir - Oct., p. 292
Zerit (use D4T)
Zintevir - Oct., p. 299